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Abstract Despite advances in therapy, outcomes for
children with pulmonary hypertension remain poor. We
sought to assess the validity of a pediatric-specific func-
tional classification system for pulmonary hypertension
(PH) in a heterogeneous population of children with PH
diagnosed by echocardiogram or cardiac catheterization. A
single-center, retrospective study of 65 infants and children
with PH was performed. Pediatric Functional Class (FC) at
diagnosis, at last visit, and change in FC over time were
evaluated for their association with mortality and PH-as-
sociated morbidity in univariate, time-to-event, and mul-
tivariate regression analyses. Median age at PH diagnosis
was 5.3 months (0 days–12.7 years). Twenty-five children
(38 %) had idiopathic PH or PH secondary to congenital
heart disease, one (2 %) had left heart disease, and 39
(60 %) had PH secondary to respiratory disease. Mortality
was 25 % (16/63), primarily in the first year of follow-up.
FC at diagnosis was not significantly associated with sur-
vival (p = 0.22), but higher FC (more impaired) at last
visit (p\ 0.001) and change in FC over time (HR 2.3,
95 % confidence interval 1.3–4, p = 0.0003) were associ-
ated with mortality. Higher FC at last visit was associated
with greater days of hospitalization in the intensive care
unit per year (p = 0.006) and history of cardiac arrest
(p = 0.012) and syncope (p = 0.02). Although pediatric
FC at diagnosis was not predictive of mortality, response to
therapy (as assessed by change in FC over time and FC at
last visit) was associated with morbidity and mortality in
this heterogeneous cohort. Multicenter prospective studies
are necessary to further validate these findings.
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Introduction
Despite significant advances in the treatment of pediatric
pulmonary hypertension (PH), outcomes for children with
PH remain poor. Prior to the availability of specific pul-
monary vasodilator therapies, median survival after diag-
nosis for children with idiopathic PH was approximately
4 years [16]. Recent data for more diverse etiologies of PH,
after the availability of targeted pulmonary vasodilator
therapy, demonstrate 5-year survival rates of 51–74 % [3,
7, 19]. Evaluation of multiple clinical and hemodynamic
factors at diagnosis in a recent meta-analysis of published
pediatric patient data showed that higher World Health
Organization (WHO) Functional Class (FC), elevated
B-type natriuretic peptide (BNP) levels, lower cardiac
index, higher pulmonary vascular resistance index (PVRi)
and right atrial pressure and lack of acute vasodilator
response were all predictive of mortality or lung trans-
plantation [13]. Further, an increase in WHO FC in chil-
dren with PH (idiopathic or secondary to congenital heart
disease) has been shown to be associated with clinical
deterioration (mortality or lung transplant) [14].
However, the WHO FC was not designed primarily for
use in children and infants. It is difficult to universally apply
theWHO FC across a wide range of developmental abilities.
Further, the effects of serious illness on growth and devel-
opment which are so important in pediatric medicine are not
considered in the WHO FC, making it less relevant to
medical decision-making in children [5, 6, 20]. The assess-
ment of WHO FC in children is further complicated by the
fact that a substantial proportion of children have more
complex and heterogeneous phenotype of PH, often with
associated disorders and syndromes that may have variable
contributions to symptoms (e.g., dyspnea and fatigue) and
function [4, 18]. In addition, syncope tends to present earlier
in the clinical course of children with PH [6]. Thus, there is
disagreement regarding the use of WHO FC as a rigorous
endpoint for clinical trials in pediatric PH [1, 6, 13, 14].
Despite these limitations, WHO FC is routinely applied to
pediatric patients in many centers and patient registries.
The recently proposed Pulmonary Vascular Research
Institute (PVRI) Functional Classification of Pulmonary
Hypertension in Children [10] (the Panama ‘‘Pediatric
Functional Class’’) was derived from the WHO Functional
Classification, with modifications made to address pedi-
atric-specific aspects of the disorder, as noted (Table 1)
[15]. Children with PH are classified into five categories (I,
II, IIIa, IIIb, IV) with five different age groups
(0–6 months, 6 months–1 year, 1–2 years, 2–5 years, and
5–16 years), based on severity of symptoms, limitations in
physical activity, and age-specific growth and develop-
mental abnormalities. The goal of this classification system
is to standardize the assessment of a child’s functional
limitations and symptoms, which may provide insight into
quality of life. To our knowledge, no studies to date have
validated this novel functional classification system with
respect to outcomes in children with PH.
Methods
Study Design
This is a retrospective cohort study of infants and children
with a diagnosis of PH who were cared for at the UCSF
Benioff Children’s Hospital and consented for enrollment
in a patient registry for children with pulmonary hyper-
tension. Children (\18 years old) were eligible for inclu-
sion in this study if they had a diagnosis of PH due to
elevated PVR confirmed by cardiac catheterization (pul-
monary artery pressure C25 mmHg and PVRi[ 3 Woods
U m2) or serial echocardiograms demonstrating persis-
tently elevated right-sided heart pressures (systemic-to-
suprasystemic) due to elevated PVR [9]. Exclusion criteria
were known terminal conditions not directly related to PH,
such as malignancies (n = 1). We included all children
enrolled in the registry from February 2012 to June 2014,
with both incident and established PH. Families of con-
secutive patients seen in our institution by the pediatric PH
service (inpatient and outpatient) were approached for
consent, under UCSF IRB approval. Written informed
consent was obtained from a parent/guardian (and assent,
as appropriate). The final sample was 65 children.
Data Collection and Pediatric Functional Class
Determination
Pediatric FC at diagnosis, 6 and 12 months later, and final
visit were coded retrospectively by two independent
reviewers using a detailed scoring rubric. Disagreements
were resolved by discussion between reviewers. Clinical
data were extracted from our database, with additional
chart review as necessary to ascertain Pediatric FC and
collect full morbidity data. Vasoreactivity was defined at
cardiac catheterization as a fall in PVR C 25 % with pre-
served cardiac index, consistent with prior reports of
challenge with increased inspired oxygen concentration
and inhaled nitric oxide [2]. If cardiac index following
vasodilator challenge was not reported, vasoreactivity was
considered indeterminate.
Data Management and Statistics
Data were analyzed by Kruskal–Wallis, Mann–Whitney, and
Chi-square tests. Time-to-event mortality data were analyzed
Pediatr Cardiol (2016) 37:756–764 757
123
by Kaplan–Meier and Cox proportional hazards; multivariate
linear regression models were generated for continuous out-
comes. Weighted kappa statistics were calculated to
determine degree of agreement between reviewers for FC.
Analyses were performed using SAS 9.4 (SAS Institute, Cary
NC). A p value\0.05 was considered significant.
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Results
Demographic, clinical, and hemodynamic characteristics of
the cohort are shown (Table 2). Female/male ratio was 1:1,
34/64 (53 %) were preterm (\37 weeks of gestational age),
and 71 % (46/65) were diagnosed in infancy (B12 months
of age). Based on the 2013 Nice classification of PH [17],
the majority (60 %) had PH secondary to a respiratory
disorder (group 3). Although 72 % had a diagnosis of
congenital heart disease (CHD), CHD was not the etiology
of PH in most of these patients. The majority (44/64, 69 %)
had a Pediatric FC of IIIb or IV at diagnosis.
Of the 65 patients in the cohort, 2 were lost to follow-up
within 6 months of our evaluation. Mortality rate of the
remaining cohort was 25.4 % (16/63) with a median age at
death of 9 months (6 months–13.5 years). Mortality was
primarily in the first year of follow-up, with no deaths after
2.5 years (Fig. 1a). At diagnostic right heart catheteriza-
tion, mean right atrial pressure was 7.3 ± 3.5 mmHg
(n = 47), mean PVRi was 10.5 ± 7.9 Woods U m2
(n = 48), and 11 of 33 patients tested and without missing
data (33 %) had acute vasoreactivity present. Notably,
some critically ill children with PH diagnosed by
echocardiogram underwent cardiac catheterization after
initiation of pulmonary vasodilator therapy.
At the time of data collection for this present study,
patients had a median of 2 prior surgeries (all non-
catheterization procedures performed in the operating
room, range 0–10) and 2 catheterizations (range 0–11).
Patients had an average of 88 and a median of 31 intensive
care unit (ICU) hospitalization days per year of life (range
0–365 days). Eighty-eight percent (57/65) had a history of
tracheal intubation (not related to a surgery or catheteri-
zation), and 86 % (56/65) had a central line in place.
Nearly half of patients (31/65, 48 %) had gastrostomy
tubes, and 11 % (7/65) had tracheostomies. Twenty percent
(13/65) had a prior syncopal event, and 18 % (12/65) had a
history of cardiac arrest. Nearly three-quarters (47/65,
72 %) of patients had received home oxygen. Forty-six
percent (30/65) of patients had received three or more PH
therapies, and 22 % (14/65) had received at least four.
Of the 16 patients who died, 15 (94 %) died in the
hospital: 12 (80 %) died in an ICU, 2 (13 %) in an emer-
gency department, and 1 (7 %) in the catheterization lab-
oratory. Patients who died in an ICU had a median length
of final hospitalization prior to death of 90 days (range
2–417 days). For two children, cause of death was
unknown. Known causes of death included respiratory
failure (7/14), cardiac arrest (6/14), and intracranial hem-
orrhage (1/14). In the 24 h prior to death, 93 % (13/14)
were intubated and patients were receiving the following
therapies: inotropic support (47 %, 8/14), nitric oxide
(71 %, 10/14), phosphodiesterase-5 (PDE5) inhibitors
(64 %, 9/14), prostacyclin derivatives (50 %, 7/14), and
endothelin receptor antagonists (ERAs) (50 %, 7/14). Half
of the children had cardiopulmonary resuscitation docu-
mented within 24 h of death; 5 patients died during
resuscitation. Eight patients (57 %) had a do-not-resusci-
tate order in place at time of death.
No patients in the cohort with Pediatric FC I or II at
diagnosis died. Mortality for children with Pediatric FC
IIIa, IIIb, and IV at diagnosis was 20 % (2/10), 46 % (6/13)
and 28 % (8/29), respectively. By Kaplan–Meier analysis,
Pediatric FC at diagnosis was not significantly predictive of
mortality (p = 0.22). However, Pediatric FC at last visit
during follow-up was significantly associated with patient
mortality (p\ 0.0001) (Fig. 1b). This remained statisti-
cally significant when controlling for PH group based on
the 2013 Nice clinical classification [17] (p = 0.003),
presence of CHD (p = 0.0009), age at diagnosis
(p = 0.001) and last visit (p = 0.0004), and preterm birth
(p = 0.003). Patients with Pediatric FC IV at their last visit
were substantially more likely to die than those with
Pediatric FC I (HR 24, 95 % CI 3.1, 187; p = 0.002).
Change in Pediatric FC over time also predicted mor-
tality (p\ 0.0001) (Fig. 1c). At any point in time, an
increase from one class to another was associated with an
increased risk of mortality (HR 2.3, 95 % CI 1.5, 3.5;
p = 0.0003). This remained significant when controlling
for PH group (p = 0.002), CHD (p = 0.001), age at
diagnosis (p = 0.0006) and last visit (p = 0.0003), and
preterm birth (p = 0.004). Patients with improvement
(decrease) in Pediatric FC between diagnosis and last visit
during follow-up had low mortality (1/35 or 3 %), com-
pared with patients with no change in FC (46 %, 10/22),
and patients with worsening (increased) FC (83 %, 5/6;
p\ 0.0001). Overall, Pediatric FC tended to improve from
time of diagnosis to last visit during follow-up (Fig. 1d).
Higher Pediatric FC at last visit was also predictive of
increased patient morbidity, including greater days of ICU
hospitalization per year (p = 0.006) and occurrence of
cardiac arrest (p = 0.012) and syncope (p = 0.02)
(Table 3). In multivariate analysis, history of syncope was
associated with an increase in Pediatric FC during follow-
up of 1.3 (p = 0.017) when adjusting for history of cardiac
arrest and days of ICU hospitalization per year. Higher
Pediatric FC at last visit was significantly associated with
history of treatment with PDE5 inhibitors (n = 46/63,
p = 0.045) but not prostacyclin derivatives (n = 19/63,
p = 0.08) or ERAs (n = 34/63, p = 0.18). There was a
trend to a greater number of lifetime PH therapies with
higher FC at last visit (p = 0.07). No significant associa-
tion was found between FC at last visit and highest
recorded lifetime BNP.
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Table 2 Patient demographic,
clinical, and hemodynamic
characteristics
Clinical characteristic (n = 65)
Age at diagnosis 5.3 months (0 days–12.7 years)
Age at enrollment 3.2 years (0.8–17.1)
Status at time of enrollment
Alive 47 (72)
Deceased 16 (25)
Lost to follow-up 2 (3)
Time elapsed from diagnosis to last visit (n = 63) 1.67 years (0.05–16.2)
Female 33 (51)
Gestational age (n = 53) 35.3 weeks (22.7–41.0)
PH classification (by Nice classification)a
Pulmonary arterial hypertension (group 1) 25 (38)
Idiopathic 5
Acquired—congenital heart disease 18
Acquired—collagen vascular disease 1
Acquired—chronic liver disease 1
Left heart disease (group 2) 1 (2)
Respiratory disorders (group 3) 39 (60)
Congenital diaphragmatic hernia 18
Bronchopulmonary dysplasia 17
Interstitial lung disease 2
Other 2
Congenital heart disease present 47 (72)
Simple (ASD, VSD, or PDA) 20 (43)
Combined (ASD ± VSD ± PDA) 13 (28)
Complex 11 (23)
Aortic coarctation 3 (6)








mRAP (mmHg) (n = 47) 7.3 ± 3.5
mPAP (mmHg) (n = 48) 42.6 ± 17.0
PCWP (mmHg) (n = 38) 9.9 ± 3.8
CI (L/min/m2) (n = 45) 3.0 ± 0.9
PVRi (U m2) (n = 48) 10.5 ± 7.9
Acute vasodilator test (n = 36)
% change in mPAP (mmHg) -17.9 ± 24.0
% change in PVRi (U m2) -30.3 ± 23.5
% change in CI (L/min/m2) 3.7 ± 18.1
Acute vasoreactivity (n = 33)c 11 (33)
Data are presented as number (%), median (range), or mean ± SD
ASD atrial septal defect, mPAP mean pulmonary artery pressure, mRAP mean right atrial pressure, PCWP
pulmonary capillary wedge pressure, PDA persistent ductus arteriosus, PVRi pulmonary vascular resistance
index, VSD ventricular septal defect
a Described in Simmoneau et al. [17]
b Cardiac catheterization was undertaken after initiation of pulmonary vasodilator therapy in some criti-
cally ill children with a diagnosis of pulmonary hypertension by serial echocardiograms demonstrating
persistent systemic-to-suprasystemic right-sided pressures
c Acute vasoreactivity defined as C25 % drop in PVRi during acute vasodilator test with preserved cardiac
index (B5 % decrease) [2]. If the cardiac index with vasodilator challenge was not recorded, the deter-
mination of vasoreactivity was not made
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Pediatric FC at diagnosis was less predictive of patient
morbidity. Although higher FC at diagnosis was signifi-
cantly associated with greater days of ICU hospitalization
per year of life (FC IV 138 ± 146 days vs. FC I
12 ± 19 days, p = 0.0001), it was not significantly asso-
ciated with hemodynamic parameters at time of diagnostic
right heart catheterization, occurrence of cardiac arrest or
syncope, treatment with prostacyclin derivatives, ERAs, or
PDE5 inhibitors, total lifetime number of PH therapies, or
highest recorded BNP level (data not shown).
Inter-rater Agreement for Pediatric Functional
Class
Of 202 determinations of Pediatric FC, there was dis-
agreement between reviewers for only 17 visits (8.4 %).
All disagreements were by no more than one category. The
most commonly observed disagreements were between
Pediatric FC IIIa and IIIb, involving children in the
6-month- to 1-year age range (6/17). Weighted kappa
demonstrated extremely high inter-rater agreement for both
initial (0.93, 95 % CI 0.87, 0.99) and final (0.96, 95 % CI
0.93, 1.0) classifications.
We also evaluated agreement between Pediatric FC and
WHO FC for initial and final visits in children[1 year (as
validation of WHO FC is in older cohorts [13]), after
collapsing Pediatric FC IIIa and IIIb into a single category.
Weighted kappa demonstrated moderate-to-strong agree-
ment at initial (median age 3.4 years, n = 19) and final
(median age 3.2 years, n = 40) visits (0.75 and 0.89,
respectively). There were 10 disagreements, with 9/10 due
to a higher Pediatric FC (III vs. II at initial visit and II vs. I
at last visit).
Discussion
In adults and older children with PH, WHO FC at diagnosis
is a consistent predictor of survival [8, 12, 13, 16]. The
Pediatric FC was proposed by the PVRI [10] to serve a
similar purpose, with modifications designed to make the
classification system universally applicable to children,
Fig. 1 a Kaplan–Meier curve for survival of entire cohort (n = 63, 2
lost to follow-up); b Kaplan–Meier curves for survival by Pediatric
Functional Class at last visit (n = 63, log rank p value \0.0001);
c Kaplan–Meier curves for survival by change in Pediatric Functional
Class between diagnosis and last visit during follow-up (n = 62, log
rank p value\0.0001); d Pediatric Functional Class at diagnosis and
last visit during follow-up (n = 64 and 63, respectively)
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while also accounting for important growth and develop-
mental effects of pediatric illness. In this study, we applied
the Pediatric FC across a group of children presenting with
diverse etiologies of PH and demonstrated that the FC at
the last visit and the change in FC during follow-up were
strongly associated with mortality and morbidity in chil-
dren with PH.
There were improvements in Pediatric FC over the time
period of the study (Fig. 1d). However, both those children
who worsened and those who failed to improve had high
rates of mortality (overall mortality 54 % for those with
lack of improvement). Consistent with this finding, Pedi-
atric FC at the last visit was strongly associated with mor-
tality and there was a trend toward an increased number of
PH-specific therapies with increasing Pediatric FC. Finally,
both the last Pediatric FC and the change in FC were
associated with various measures of morbidity. Taken
together, these data strongly suggest that the Pediatric FC is
a valid assessment of disease severity in pediatric PH. Thus,
Pediatric FC should be evaluated and documented for all
children with PH throughout the course of their follow-up.
Failure to improve Pediatric FC may prompt additional
discussions with families about prognosis and goals of care.
Our data show the Pediatric FC is responsive to treat-
ment in a diverse cohort of children with PH (which has
previously been shown with respect to the WHO FC in
children with predominantly group 1 PH). There is a
challenge in defining endpoints for clinical trials in pedi-
atric PH, given that most standard assessments of disease
severity cannot be applied to all children, with the possible
exception of the invasive measurement of hemodynamics
[6]. WHO FC has been proposed as an endpoint for clinical
trials of therapies for PH in children, despite its limitations
in the pediatric population [14]. We demonstrate excellent
inter-rater agreement for Pediatric FC, making it a reliable
measurement. Further, we demonstrate strong agreement
with WHO FC in children [1 year, although most dis-
agreements were due to higher assignment of the Pediatric
FC, likely due to consideration of growth and develop-
mental status. Thus, there is potential for the use of Pedi-
atric FC as part of rigorous baseline and outcome
assessments for research in pediatric PH, if the data pre-
sented here are replicated in other cohorts [6, 14].
Pediatric FC at diagnosis was not predictive of mortality
in this cohort, nor was it substantially predictive of mor-
bidity; the only significant relationship was with ICU days.
This is likely because many of the children in the cohort
were critically ill at time of diagnosis and therefore were
assigned a high FC. As noted, our cohort includes more
diverse etiologies of PH than many studies in the literature
have presented, with a predominance of group 3 PH (as-
sociated with respiratory disorders), whereas generally
[90 % of the children have group 1 PH in other published
cohorts (summarized by Ploegstra et al. 2015) [13]. In
contrast to these reports, in a recent paper from a multi-
center Spanish registry (including both referral and non-
referral centers), only 63 % of the children had group 1 PH
and 18 % had group 3 PH; overall, 31 % were considered
to have multifactorial PH [4]. Similarly, a recent US-based
study from an administrative dataset of pediatric hospital
admissions (Kids’ Inpatient Database, KID) shows an
increasing trend toward resource utilization in children
with PH who do not have CHD [11]. Thus, our unrestricted
cohort may be more representative of children with the
types of pulmonary hypertensive vascular disorders seen in
pediatric PH programs than the more limited patient pop-
ulations that have been previously analyzed with respect to
WHO FC.
Table 3 Pediatric Functional Class at last visit and patient morbidity
Characteristic Pediatric Functional Class p value
I (n = 21) II (n = 17) IIIa (n = 4) IIIb (n = 4) IV (n = 15)
ICU hospitalization (days/year) 20 (0–181) 29 (1–181) 18 (1–24) 29 (7–171) 361 (2–365) 0.006
History of cardiac arrest 1 (5) 3 (17) 0 (0) 1 (25) 6 (40) 0.01
History of syncope 1 (5) 4 (22) 1 (20) 2 (50) 5 (33) 0.02
PH-specific therapies (total number)a 2 (0–5) 2 (0–7) 2 (1–5) 3.5 (2–5) 3 (1–6) 0.07
Treatment with PDE5 inhibitor 12 (57) 13 (72) 5 (100) 4 (100) 12 (80) 0.045
Treatment with prostacyclin derivative 5 (24) 3 (17) 1 (20) 3 (75) 7 (47) 0.08
Treatment with ERA 8 (38) 12 (67) 2 (40) 3 (75) 9 (60) 0.18
Data are presented as number (%) or median (range)
ICU intensive care unit, PDE5 phosphodiesterase 5, PH pulmonary hypertension, ERA endothelin receptor antagonist
a PH-specific therapies are defined as medications with regulatory approval for treatment of PH in any patient population
 By Kruskal–Wallis for continuous and Chi-square for categorical outcomes
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Consistent with the diverse etiologies of PH in our
cohort, the patient population described here is consider-
ably younger than those in previously published cohorts
(summarized by Ploegstra et al. 2015). A national trend
toward decreasing age of admitted children with PH was
also demonstrated in the KID data, over the 15 years pre-
ceding our study [11]. Given the increasingly high resource
utilization and cost associated with pediatric PH [11], it
will be important to better understand these emerging
patient populations of infants and children with PH, so
strategies and therapies to improve outcomes can be
investigated.
This study has several important limitations. Pediatric
FC was coded retrospectively based on chart review, which
depended on the quality and detail of patient medical
records. However, we demonstrate very high agreement
between our two reviewers utilizing a scoring rubric, mit-
igating this concern. Additionally, although our cohort of
patients was from a single institution, which may limit
generalizability, we have described a more diverse group of
patients with pediatric PH than many prior publications,
and this may, in fact, be more representative of children
with PH cared for across the USA [11]. Finally, we were
limited by the small number of children in each FC group,
which likely impacted our ability to identify a statistically
significant relationship between FC at diagnosis and
mortality.
In conclusion, we have demonstrated strong validity for
the novel Pediatric FC as a measure of illness severity in a
diverse group of children with PH. Combined with the
extremely high level of inter-rater reliability we have
shown, this study suggests that the Pediatric FC may be an
appropriate metric for the description and assessment of
children with PH. We are currently assigning the Pediatric
FC prospectively at each visit for all of our patients, and
following the trajectory of these assessments. The findings
from the current study should be confirmed in multicenter,
prospective studies.
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